Atomwise could receive up to US$1.5 billion to develop first in-class and best in-class small molecules through partnership with China’s leading biopharmaceutical company, Hansoh Pharma.
Mark Terry of BioSpace reports on Atomwise’s three new joint ventures.
Atomwise and Atropos Therapeutics form a joint venture to discover and develop anticancer agents using senescence assay and AI technologies.
Joint venture brings together AI technology and living tumor organoids to develop novel personalized therapies for cancer patients SEATTLE, Wash., and SAN FRANCISCO, Calif. – SEngine Precision Medicine and Atomwise, Inc. today announced a joint venture to accelerate novel oncology drug discovery utilizing the unique platform technologies each company has validated through years of development. […]
Ann Arbor, Michigan – From making pain management safer and more effective to identifying inhibitors for a fibrosis target protein and more, researchers from Michigan Medicine, as well as the University of Michigan College of Pharmacy and U-M Life Sciences Institute, are looking to advance their projects through Atomwise’s Artificial Intelligence Molecular Screen (AIMS) Awards […]
Having signed a multi-year, multi-target agreement with Lilly worth potentially $550m, Atomwise CEO Abe Heifets tells Scrip the burden of proof is on AI practitioners to start producing relevant and actionable data.